Navigation Links
TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
Date:4/1/2008

NATICK, Mass. and CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomized clinical trials. The analysis compared the safety and efficacy of the TAXUS(R) Express(TM) Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased rates of mortality and restenosis for diabetics versus non-diabetics in patients with cardiovascular disease(1), the TAXUS Stent had comparable levels of late loss and target lesion revascularization (TLR) across these patient populations. The study also showed no significant differences in target vessel revascularization (TVR), stent thrombosis, or myocardial infarction (MI), after adjustments were made for differences in other baseline characteristics between patients with or without diabetes. Analysis of the data was presented by Gregg W. Stone, M.D., of the Columbia University Medical Center in New York, at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

"The TAXUS IV/V diabetic subset data indicated that the TAXUS Stent mitigated the impact of diabetes as a risk factor for restenosis following stenting procedures in the patients studied," said Dr. Stone. "Diabetic patients treated with TAXUS Stents compared to bare-metal stents had significantly improved event-free survival, particularly important in high-risk patients with diabetes."

The pooled analysis included angiographic outcomes at nine months and clinical outcomes at three years among 338 diabetic patients and 901 non-diabetic patients treated with the TAXUS Stent from the TAXUS IV and V clinical t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
2. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
6. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
7. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
10. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Calif., June 2, 2011 DURECT Corporation (Nasdaq: ... Chief Medical Officer and Executive Vice President, Corporate Strategy ... opportunities.  Dr. Stauffer and DURECT have entered into a ... (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) "We appreciate all ...
... SAN DIEGO, June 2, 2011 Biocept, Inc. today ... a poster at the 2011 Annual Meeting of the ... Chicago, Illinois June 3-7. The poster presentation is based ... logy C ell E nrichment and ...
Cached Medicine Technology:DURECT Announces Resignation of Chief Medical Officer 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 3
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... Dr. Steven Shoshany of New ... , to coincide with an exciting new direction he is taking with his office and an ... New York ... in New York City for more than 13 years in his SOHO office. He recently launched ...
... ... , ... Ind. (Vocus) June 23, 2009 -- Press Ganey Associates, Inc., the health care industry,s ... Patient Perspectives on American Health Care., According to the report, patients now spend an ...
... CetylMax, LLC and Flexadren, LLC, manufacturers and distributors of ... aiding in joint support and pain relief, announced today ... Celadrin, did not prevail in its claims against CetylMax(R) ... the Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix. ...
... With yet another tragedy in the headlines, Pennsylvania residents ... residents of our state,s assisted living facilities. , ... such as those that forced the Department of Public ... , , Earlier this month, an aide at ...
... June 22 Providence Tarzana Medical Center on Friday ... generation in imaging - the Ziehm Vision RFD - in this ... of a patient who had suffered a small stroke. , ... staff at Tarzana, liked what he saw in the crystal-clear image ...
... Seabrook House is proud to announce their sponsorship of "How ... Lamm, BRI-I, CAI. , , Founder of Intervention ... a nationally recognized Board-Registered Interventionist, Brad Lamm BRI-I, CAI, will ... 2009 at 6:30pm at The Radnor in St. Davids, PA ...
Cached Medicine News:Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 2Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 3Health News:Patients Spent an Average of Four Hours and Three Minutes in U.S. Emergency Departments in 2008, According to Latest Press Ganey Report 4Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 2Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 3Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:'How to Change Someone You Love' Offers Help to Those Who Feel Powerless in the Face of Addiction 2
For the qualitative detection of group A Streptococcal antigen from throat swabs...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine or serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
Medicine Products: